nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—BLK—systemic scleroderma	0.602	1	CbGaD
Afatinib—ABCG2—Leflunomide—systemic scleroderma	0.064	0.332	CbGbCtD
Afatinib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0396	0.205	CbGbCtD
Afatinib—ABCB1—Lisinopril—systemic scleroderma	0.0242	0.125	CbGbCtD
Afatinib—ABCB1—Captopril—systemic scleroderma	0.0181	0.0938	CbGbCtD
Afatinib—ABCG2—Methotrexate—systemic scleroderma	0.0159	0.0821	CbGbCtD
Afatinib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0143	0.0738	CbGbCtD
Afatinib—ABCB1—Prednisone—systemic scleroderma	0.0114	0.059	CbGbCtD
Afatinib—ABCB1—Methotrexate—systemic scleroderma	0.00572	0.0296	CbGbCtD
Afatinib—Vandetanib—BLK—systemic scleroderma	0.00285	1	CrCbGaD
Afatinib—DYRK1A—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.00239	0.697	CbGdCrCtD
Afatinib—ERBB2—connective tissue—systemic scleroderma	0.00141	0.079	CbGeAlD
Afatinib—ERBB2—smooth muscle tissue—systemic scleroderma	0.00129	0.0722	CbGeAlD
Afatinib—ERBB2—skin of body—systemic scleroderma	0.00127	0.0713	CbGeAlD
Afatinib—PHKG2—tendon—systemic scleroderma	0.00108	0.0604	CbGeAlD
Afatinib—ERBB2—digestive system—systemic scleroderma	0.00102	0.057	CbGeAlD
Afatinib—ERBB4—tendon—systemic scleroderma	0.000968	0.0543	CbGeAlD
Afatinib—IRAK1—smooth muscle tissue—systemic scleroderma	0.000963	0.054	CbGeAlD
Afatinib—PHKG2—lung—systemic scleroderma	0.000944	0.053	CbGeAlD
Afatinib—ERBB2—lung—systemic scleroderma	0.000849	0.0476	CbGeAlD
Afatinib—ERBB4—lung—systemic scleroderma	0.000849	0.0476	CbGeAlD
Afatinib—DYRK1A—lung—systemic scleroderma	0.000817	0.0459	CbGeAlD
Afatinib—IRAK1—tendon—systemic scleroderma	0.000724	0.0406	CbGeAlD
Afatinib—EGFR—lung—systemic scleroderma	0.00072	0.0404	CbGeAlD
Afatinib—IRAK1—lung—systemic scleroderma	0.000635	0.0356	CbGeAlD
Afatinib—LCK—lung—systemic scleroderma	0.000619	0.0348	CbGeAlD
Afatinib—ABL1—connective tissue—systemic scleroderma	0.00059	0.0331	CbGeAlD
Afatinib—ABL1—smooth muscle tissue—systemic scleroderma	0.00054	0.0303	CbGeAlD
Afatinib—ABL1—skin of body—systemic scleroderma	0.000533	0.0299	CbGeAlD
Afatinib—ABL1—digestive system—systemic scleroderma	0.000426	0.0239	CbGeAlD
Afatinib—ABL1—tendon—systemic scleroderma	0.000405	0.0227	CbGeAlD
Afatinib—ABCB1—blood vessel—systemic scleroderma	0.000358	0.0201	CbGeAlD
Afatinib—ABL1—lung—systemic scleroderma	0.000356	0.02	CbGeAlD
Afatinib—Sepsis—Prednisone—systemic scleroderma	0.00026	0.0027	CcSEcCtD
Afatinib—ERBB2—Exemestane—Prednisone—systemic scleroderma	0.000259	0.0756	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Mometasone—systemic scleroderma	0.000259	0.0756	CbGdCrCtD
Afatinib—Mental disorder—Leflunomide—systemic scleroderma	0.000259	0.00268	CcSEcCtD
Afatinib—Dyspnoea—Mometasone—systemic scleroderma	0.000258	0.00268	CcSEcCtD
Afatinib—Malnutrition—Leflunomide—systemic scleroderma	0.000257	0.00266	CcSEcCtD
Afatinib—Dyspepsia—Mometasone—systemic scleroderma	0.000255	0.00264	CcSEcCtD
Afatinib—Mediastinal disorder—Mycophenolic acid—systemic scleroderma	0.000254	0.00263	CcSEcCtD
Afatinib—Decreased appetite—Mometasone—systemic scleroderma	0.000252	0.00261	CcSEcCtD
Afatinib—Dysgeusia—Leflunomide—systemic scleroderma	0.000252	0.00261	CcSEcCtD
Afatinib—Weight decreased—Mycophenolate mofetil—systemic scleroderma	0.000251	0.0026	CcSEcCtD
Afatinib—Urinary tract disorder—Lisinopril—systemic scleroderma	0.000251	0.0026	CcSEcCtD
Afatinib—Fatigue—Mometasone—systemic scleroderma	0.00025	0.00259	CcSEcCtD
Afatinib—Pneumonia—Mycophenolate mofetil—systemic scleroderma	0.000249	0.00258	CcSEcCtD
Afatinib—Alopecia—Mycophenolic acid—systemic scleroderma	0.000249	0.00258	CcSEcCtD
Afatinib—Urethral disorder—Lisinopril—systemic scleroderma	0.000249	0.00258	CcSEcCtD
Afatinib—Back pain—Leflunomide—systemic scleroderma	0.000249	0.00258	CcSEcCtD
Afatinib—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.000248	0.00257	CcSEcCtD
Afatinib—Infestation—Mycophenolate mofetil—systemic scleroderma	0.000248	0.00257	CcSEcCtD
Afatinib—Muscle spasms—Leflunomide—systemic scleroderma	0.000247	0.00256	CcSEcCtD
Afatinib—Mental disorder—Mycophenolic acid—systemic scleroderma	0.000247	0.00256	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Mometasone—systemic scleroderma	0.000246	0.0718	CbGdCrCtD
Afatinib—Malnutrition—Mycophenolic acid—systemic scleroderma	0.000245	0.00254	CcSEcCtD
Afatinib—Cystitis noninfective—Methotrexate—systemic scleroderma	0.000245	0.00254	CcSEcCtD
Afatinib—Renal failure—Mycophenolate mofetil—systemic scleroderma	0.000243	0.00252	CcSEcCtD
Afatinib—Cystitis—Methotrexate—systemic scleroderma	0.000242	0.00251	CcSEcCtD
Afatinib—Stomatitis—Mycophenolate mofetil—systemic scleroderma	0.000241	0.0025	CcSEcCtD
Afatinib—Asthenia—Pentoxifylline—systemic scleroderma	0.000241	0.0025	CcSEcCtD
Afatinib—Conjunctivitis—Mycophenolate mofetil—systemic scleroderma	0.000241	0.0025	CcSEcCtD
Afatinib—Urinary tract infection—Mycophenolate mofetil—systemic scleroderma	0.000241	0.0025	CcSEcCtD
Afatinib—Pruritus—Pentoxifylline—systemic scleroderma	0.000238	0.00246	CcSEcCtD
Afatinib—Back pain—Mycophenolic acid—systemic scleroderma	0.000237	0.00246	CcSEcCtD
Afatinib—Muscle spasms—Mycophenolic acid—systemic scleroderma	0.000236	0.00244	CcSEcCtD
Afatinib—Hepatobiliary disease—Mycophenolate mofetil—systemic scleroderma	0.000234	0.00243	CcSEcCtD
Afatinib—Epistaxis—Mycophenolate mofetil—systemic scleroderma	0.000234	0.00242	CcSEcCtD
Afatinib—Insomnia—Captopril—systemic scleroderma	0.00023	0.00239	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00023	0.00239	CcSEcCtD
Afatinib—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00023	0.00238	CcSEcCtD
Afatinib—Body temperature increased—Mometasone—systemic scleroderma	0.000229	0.00237	CcSEcCtD
Afatinib—Mediastinal disorder—Lisinopril—systemic scleroderma	0.000229	0.00237	CcSEcCtD
Afatinib—Dyspnoea—Captopril—systemic scleroderma	0.000227	0.00235	CcSEcCtD
Afatinib—Mouth ulceration—Methotrexate—systemic scleroderma	0.000227	0.00235	CcSEcCtD
Afatinib—Bladder pain—Methotrexate—systemic scleroderma	0.000227	0.00235	CcSEcCtD
Afatinib—ABCG2—lung—systemic scleroderma	0.000224	0.0126	CbGeAlD
Afatinib—Cough—Leflunomide—systemic scleroderma	0.000224	0.00233	CcSEcCtD
Afatinib—Alopecia—Lisinopril—systemic scleroderma	0.000224	0.00232	CcSEcCtD
Afatinib—Dyspepsia—Captopril—systemic scleroderma	0.000224	0.00232	CcSEcCtD
Afatinib—Mental disorder—Lisinopril—systemic scleroderma	0.000222	0.0023	CcSEcCtD
Afatinib—Dizziness—Pentoxifylline—systemic scleroderma	0.000222	0.0023	CcSEcCtD
Afatinib—Decreased appetite—Captopril—systemic scleroderma	0.000221	0.00229	CcSEcCtD
Afatinib—Malnutrition—Lisinopril—systemic scleroderma	0.000221	0.00229	CcSEcCtD
Afatinib—Infection—Azathioprine—systemic scleroderma	0.000221	0.00229	CcSEcCtD
Afatinib—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.00022	0.00228	CcSEcCtD
Afatinib—Fatigue—Captopril—systemic scleroderma	0.000219	0.00227	CcSEcCtD
Afatinib—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.000218	0.00226	CcSEcCtD
Afatinib—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.000218	0.00226	CcSEcCtD
Afatinib—Constipation—Captopril—systemic scleroderma	0.000218	0.00226	CcSEcCtD
Afatinib—Sepsis—Methotrexate—systemic scleroderma	0.000218	0.00226	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000217	0.00225	CcSEcCtD
Afatinib—Dysgeusia—Lisinopril—systemic scleroderma	0.000216	0.00224	CcSEcCtD
Afatinib—Skin disorder—Azathioprine—systemic scleroderma	0.000216	0.00224	CcSEcCtD
Afatinib—Cough—Mycophenolic acid—systemic scleroderma	0.000214	0.00222	CcSEcCtD
Afatinib—Back pain—Lisinopril—systemic scleroderma	0.000214	0.00221	CcSEcCtD
Afatinib—Vomiting—Pentoxifylline—systemic scleroderma	0.000214	0.00221	CcSEcCtD
Afatinib—Muscle spasms—Lisinopril—systemic scleroderma	0.000212	0.0022	CcSEcCtD
Afatinib—Rash—Pentoxifylline—systemic scleroderma	0.000212	0.0022	CcSEcCtD
Afatinib—Dermatitis—Pentoxifylline—systemic scleroderma	0.000212	0.00219	CcSEcCtD
Afatinib—Headache—Pentoxifylline—systemic scleroderma	0.00021	0.00218	CcSEcCtD
Afatinib—Infection—Leflunomide—systemic scleroderma	0.000208	0.00216	CcSEcCtD
Afatinib—Asthenia—Mometasone—systemic scleroderma	0.000208	0.00216	CcSEcCtD
Afatinib—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000208	0.00215	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000207	0.00215	CcSEcCtD
Afatinib—Nervous system disorder—Leflunomide—systemic scleroderma	0.000206	0.00213	CcSEcCtD
Afatinib—Pruritus—Mometasone—systemic scleroderma	0.000205	0.00213	CcSEcCtD
Afatinib—Skin disorder—Leflunomide—systemic scleroderma	0.000204	0.00211	CcSEcCtD
Afatinib—Body temperature increased—Captopril—systemic scleroderma	0.000201	0.00209	CcSEcCtD
Afatinib—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.0002	0.00208	CcSEcCtD
Afatinib—Dry skin—Prednisone—systemic scleroderma	0.0002	0.00207	CcSEcCtD
Afatinib—Nausea—Pentoxifylline—systemic scleroderma	0.0002	0.00207	CcSEcCtD
Afatinib—Infection—Mycophenolic acid—systemic scleroderma	0.000199	0.00206	CcSEcCtD
Afatinib—Diarrhoea—Mometasone—systemic scleroderma	0.000198	0.00206	CcSEcCtD
Afatinib—Hypokalaemia—Prednisone—systemic scleroderma	0.000198	0.00205	CcSEcCtD
Afatinib—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000196	0.00204	CcSEcCtD
Afatinib—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000196	0.00203	CcSEcCtD
Afatinib—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000195	0.00202	CcSEcCtD
Afatinib—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000194	0.00201	CcSEcCtD
Afatinib—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000194	0.00201	CcSEcCtD
Afatinib—Cough—Lisinopril—systemic scleroderma	0.000193	0.002	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000192	0.00199	CcSEcCtD
Afatinib—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000192	0.00199	CcSEcCtD
Afatinib—Insomnia—Leflunomide—systemic scleroderma	0.00019	0.00197	CcSEcCtD
Afatinib—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00019	0.00196	CcSEcCtD
Afatinib—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000187	0.00194	CcSEcCtD
Afatinib—Dyspnoea—Leflunomide—systemic scleroderma	0.000187	0.00194	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000187	0.00194	CcSEcCtD
Afatinib—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000186	0.00193	CcSEcCtD
Afatinib—Dyspepsia—Leflunomide—systemic scleroderma	0.000185	0.00191	CcSEcCtD
Afatinib—Vomiting—Mometasone—systemic scleroderma	0.000184	0.00191	CcSEcCtD
Afatinib—Rash—Mometasone—systemic scleroderma	0.000183	0.00189	CcSEcCtD
Afatinib—Asthenia—Captopril—systemic scleroderma	0.000183	0.00189	CcSEcCtD
Afatinib—Dermatitis—Mometasone—systemic scleroderma	0.000183	0.00189	CcSEcCtD
Afatinib—Decreased appetite—Leflunomide—systemic scleroderma	0.000182	0.00189	CcSEcCtD
Afatinib—Headache—Mometasone—systemic scleroderma	0.000182	0.00188	CcSEcCtD
Afatinib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000181	0.00188	CcSEcCtD
Afatinib—Insomnia—Mycophenolic acid—systemic scleroderma	0.000181	0.00188	CcSEcCtD
Afatinib—Fatigue—Leflunomide—systemic scleroderma	0.000181	0.00187	CcSEcCtD
Afatinib—Pruritus—Captopril—systemic scleroderma	0.00018	0.00187	CcSEcCtD
Afatinib—Constipation—Leflunomide—systemic scleroderma	0.000179	0.00186	CcSEcCtD
Afatinib—Infection—Lisinopril—systemic scleroderma	0.000179	0.00186	CcSEcCtD
Afatinib—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000178	0.00185	CcSEcCtD
Afatinib—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000176	0.00183	CcSEcCtD
Afatinib—Body temperature increased—Azathioprine—systemic scleroderma	0.000176	0.00182	CcSEcCtD
Afatinib—Skin disorder—Lisinopril—systemic scleroderma	0.000175	0.00181	CcSEcCtD
Afatinib—Diarrhoea—Captopril—systemic scleroderma	0.000174	0.00181	CcSEcCtD
Afatinib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000174	0.0018	CcSEcCtD
Afatinib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000173	0.00179	CcSEcCtD
Afatinib—Fatigue—Mycophenolic acid—systemic scleroderma	0.000173	0.00179	CcSEcCtD
Afatinib—Nausea—Mometasone—systemic scleroderma	0.000172	0.00178	CcSEcCtD
Afatinib—Constipation—Mycophenolic acid—systemic scleroderma	0.000171	0.00177	CcSEcCtD
Afatinib—Weight decreased—Prednisone—systemic scleroderma	0.00017	0.00177	CcSEcCtD
Afatinib—Cough—Mycophenolate mofetil—systemic scleroderma	0.000169	0.00175	CcSEcCtD
Afatinib—Dizziness—Captopril—systemic scleroderma	0.000168	0.00174	CcSEcCtD
Afatinib—Body temperature increased—Leflunomide—systemic scleroderma	0.000166	0.00172	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000164	0.0017	CcSEcCtD
Afatinib—Insomnia—Lisinopril—systemic scleroderma	0.000163	0.00169	CcSEcCtD
Afatinib—Vomiting—Captopril—systemic scleroderma	0.000162	0.00168	CcSEcCtD
Afatinib—Dyspnoea—Lisinopril—systemic scleroderma	0.000161	0.00167	CcSEcCtD
Afatinib—Rash—Captopril—systemic scleroderma	0.000161	0.00166	CcSEcCtD
Afatinib—Dermatitis—Captopril—systemic scleroderma	0.00016	0.00166	CcSEcCtD
Afatinib—Headache—Captopril—systemic scleroderma	0.000159	0.00165	CcSEcCtD
Afatinib—Dyspepsia—Lisinopril—systemic scleroderma	0.000159	0.00164	CcSEcCtD
Afatinib—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000158	0.00164	CcSEcCtD
Afatinib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000157	0.00163	CcSEcCtD
Afatinib—Decreased appetite—Lisinopril—systemic scleroderma	0.000157	0.00162	CcSEcCtD
Afatinib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000156	0.00161	CcSEcCtD
Afatinib—Fatigue—Lisinopril—systemic scleroderma	0.000155	0.00161	CcSEcCtD
Afatinib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000155	0.00161	CcSEcCtD
Afatinib—Constipation—Lisinopril—systemic scleroderma	0.000154	0.0016	CcSEcCtD
Afatinib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000153	0.00159	CcSEcCtD
Afatinib—Diarrhoea—Azathioprine—systemic scleroderma	0.000152	0.00158	CcSEcCtD
Afatinib—Nausea—Captopril—systemic scleroderma	0.000151	0.00157	CcSEcCtD
Afatinib—Asthenia—Leflunomide—systemic scleroderma	0.000151	0.00156	CcSEcCtD
Afatinib—Pruritus—Leflunomide—systemic scleroderma	0.000148	0.00154	CcSEcCtD
Afatinib—Connective tissue disorder—Prednisone—systemic scleroderma	0.000148	0.00153	CcSEcCtD
Afatinib—Dizziness—Azathioprine—systemic scleroderma	0.000147	0.00152	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000146	0.00152	CcSEcCtD
Afatinib—Asthenia—Mycophenolic acid—systemic scleroderma	0.000144	0.00149	CcSEcCtD
Afatinib—Diarrhoea—Leflunomide—systemic scleroderma	0.000144	0.00149	CcSEcCtD
Afatinib—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00148	CcSEcCtD
Afatinib—Body temperature increased—Lisinopril—systemic scleroderma	0.000143	0.00148	CcSEcCtD
Afatinib—Pruritus—Mycophenolic acid—systemic scleroderma	0.000142	0.00147	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Prednisone—systemic scleroderma	0.000141	0.0412	CbGdCrCtD
Afatinib—Vomiting—Azathioprine—systemic scleroderma	0.000141	0.00146	CcSEcCtD
Afatinib—Pneumonia—Methotrexate—systemic scleroderma	0.000141	0.00146	CcSEcCtD
Afatinib—Eye disorder—Prednisone—systemic scleroderma	0.000141	0.00146	CcSEcCtD
Afatinib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000141	0.00146	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—systemic scleroderma	0.00014	0.00145	CcSEcCtD
Afatinib—Infestation—Methotrexate—systemic scleroderma	0.00014	0.00145	CcSEcCtD
Afatinib—Rash—Azathioprine—systemic scleroderma	0.00014	0.00145	CcSEcCtD
Afatinib—Dermatitis—Azathioprine—systemic scleroderma	0.00014	0.00145	CcSEcCtD
Afatinib—Headache—Azathioprine—systemic scleroderma	0.000139	0.00144	CcSEcCtD
Afatinib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000139	0.00144	CcSEcCtD
Afatinib—Dizziness—Leflunomide—systemic scleroderma	0.000139	0.00144	CcSEcCtD
Afatinib—Renal failure—Methotrexate—systemic scleroderma	0.000138	0.00143	CcSEcCtD
Afatinib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000137	0.00142	CcSEcCtD
Afatinib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000137	0.00142	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—systemic scleroderma	0.000137	0.00142	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—systemic scleroderma	0.000136	0.00141	CcSEcCtD
Afatinib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000136	0.00141	CcSEcCtD
Afatinib—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000135	0.0014	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Prednisone—systemic scleroderma	0.000134	0.0391	CbGdCrCtD
Afatinib—Vomiting—Leflunomide—systemic scleroderma	0.000133	0.00138	CcSEcCtD
Afatinib—Alopecia—Prednisone—systemic scleroderma	0.000133	0.00138	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000133	0.00138	CcSEcCtD
Afatinib—ABCB1—digestive system—systemic scleroderma	0.000132	0.00743	CbGeAlD
Afatinib—Dizziness—Mycophenolic acid—systemic scleroderma	0.000132	0.00137	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—systemic scleroderma	0.000132	0.00137	CcSEcCtD
Afatinib—Rash—Leflunomide—systemic scleroderma	0.000132	0.00137	CcSEcCtD
Afatinib—Dermatitis—Leflunomide—systemic scleroderma	0.000132	0.00137	CcSEcCtD
Afatinib—Mental disorder—Prednisone—systemic scleroderma	0.000132	0.00137	CcSEcCtD
Afatinib—Nausea—Azathioprine—systemic scleroderma	0.000132	0.00137	CcSEcCtD
Afatinib—Headache—Leflunomide—systemic scleroderma	0.000131	0.00136	CcSEcCtD
Afatinib—Malnutrition—Prednisone—systemic scleroderma	0.000131	0.00136	CcSEcCtD
Afatinib—Asthenia—Lisinopril—systemic scleroderma	0.000129	0.00134	CcSEcCtD
Afatinib—Pruritus—Lisinopril—systemic scleroderma	0.000128	0.00132	CcSEcCtD
Afatinib—Vomiting—Mycophenolic acid—systemic scleroderma	0.000127	0.00132	CcSEcCtD
Afatinib—Rash—Mycophenolic acid—systemic scleroderma	0.000126	0.00131	CcSEcCtD
Afatinib—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000126	0.00131	CcSEcCtD
Afatinib—Headache—Mycophenolic acid—systemic scleroderma	0.000125	0.0013	CcSEcCtD
Afatinib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000125	0.00129	CcSEcCtD
Afatinib—Nausea—Leflunomide—systemic scleroderma	0.000125	0.00129	CcSEcCtD
Afatinib—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000124	0.00129	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—systemic scleroderma	0.000123	0.00128	CcSEcCtD
Afatinib—Diarrhoea—Lisinopril—systemic scleroderma	0.000123	0.00128	CcSEcCtD
Afatinib—Dizziness—Lisinopril—systemic scleroderma	0.000119	0.00124	CcSEcCtD
Afatinib—Nausea—Mycophenolic acid—systemic scleroderma	0.000119	0.00123	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—systemic scleroderma	0.000118	0.00122	CcSEcCtD
Afatinib—Vomiting—Lisinopril—systemic scleroderma	0.000115	0.00119	CcSEcCtD
Afatinib—Rash—Lisinopril—systemic scleroderma	0.000114	0.00118	CcSEcCtD
Afatinib—Dermatitis—Lisinopril—systemic scleroderma	0.000114	0.00118	CcSEcCtD
Afatinib—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000114	0.00118	CcSEcCtD
Afatinib—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000113	0.00117	CcSEcCtD
Afatinib—Headache—Lisinopril—systemic scleroderma	0.000113	0.00117	CcSEcCtD
Afatinib—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000112	0.00116	CcSEcCtD
Afatinib—Alopecia—Methotrexate—systemic scleroderma	0.000111	0.00115	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000111	0.00115	CcSEcCtD
Afatinib—ABCB1—lung—systemic scleroderma	0.000111	0.00621	CbGeAlD
Afatinib—Mental disorder—Methotrexate—systemic scleroderma	0.00011	0.00114	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—systemic scleroderma	0.00011	0.00114	CcSEcCtD
Afatinib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000108	0.00112	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—systemic scleroderma	0.000107	0.00111	CcSEcCtD
Afatinib—Nausea—Lisinopril—systemic scleroderma	0.000107	0.00111	CcSEcCtD
Afatinib—Infection—Prednisone—systemic scleroderma	0.000106	0.0011	CcSEcCtD
Afatinib—Back pain—Methotrexate—systemic scleroderma	0.000106	0.0011	CcSEcCtD
Afatinib—Nervous system disorder—Prednisone—systemic scleroderma	0.000105	0.00109	CcSEcCtD
Afatinib—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000104	0.00108	CcSEcCtD
Afatinib—Skin disorder—Prednisone—systemic scleroderma	0.000104	0.00108	CcSEcCtD
Afatinib—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.0001	0.00104	CcSEcCtD
Afatinib—Rash—Mycophenolate mofetil—systemic scleroderma	9.96e-05	0.00103	CcSEcCtD
Afatinib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	9.95e-05	0.00103	CcSEcCtD
Afatinib—Headache—Mycophenolate mofetil—systemic scleroderma	9.89e-05	0.00103	CcSEcCtD
Afatinib—Insomnia—Prednisone—systemic scleroderma	9.68e-05	0.001	CcSEcCtD
Afatinib—Cough—Methotrexate—systemic scleroderma	9.57e-05	0.000992	CcSEcCtD
Afatinib—Dyspepsia—Prednisone—systemic scleroderma	9.42e-05	0.000977	CcSEcCtD
Afatinib—Nausea—Mycophenolate mofetil—systemic scleroderma	9.38e-05	0.000972	CcSEcCtD
Afatinib—Decreased appetite—Prednisone—systemic scleroderma	9.31e-05	0.000965	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	9.27e-05	0.000961	CcSEcCtD
Afatinib—Fatigue—Prednisone—systemic scleroderma	9.23e-05	0.000957	CcSEcCtD
Afatinib—Constipation—Prednisone—systemic scleroderma	9.16e-05	0.000949	CcSEcCtD
Afatinib—Infection—Methotrexate—systemic scleroderma	8.89e-05	0.000921	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—systemic scleroderma	8.77e-05	0.00091	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—systemic scleroderma	8.69e-05	0.000901	CcSEcCtD
Afatinib—Body temperature increased—Prednisone—systemic scleroderma	8.46e-05	0.000877	CcSEcCtD
Afatinib—Insomnia—Methotrexate—systemic scleroderma	8.09e-05	0.000839	CcSEcCtD
Afatinib—Dyspnoea—Methotrexate—systemic scleroderma	7.98e-05	0.000827	CcSEcCtD
Afatinib—Dyspepsia—Methotrexate—systemic scleroderma	7.88e-05	0.000816	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—systemic scleroderma	7.78e-05	0.000806	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	7.72e-05	0.000801	CcSEcCtD
Afatinib—Fatigue—Methotrexate—systemic scleroderma	7.71e-05	0.0008	CcSEcCtD
Afatinib—Asthenia—Prednisone—systemic scleroderma	7.68e-05	0.000796	CcSEcCtD
Afatinib—Pruritus—Prednisone—systemic scleroderma	7.57e-05	0.000785	CcSEcCtD
Afatinib—Diarrhoea—Prednisone—systemic scleroderma	7.33e-05	0.000759	CcSEcCtD
Afatinib—Dizziness—Prednisone—systemic scleroderma	7.08e-05	0.000734	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—systemic scleroderma	7.07e-05	0.000733	CcSEcCtD
Afatinib—ABL1—Hemostasis—CSK—systemic scleroderma	6.98e-05	0.000833	CbGpPWpGaD
Afatinib—Vomiting—Prednisone—systemic scleroderma	6.81e-05	0.000706	CcSEcCtD
Afatinib—LCK—Hemostasis—SELP—systemic scleroderma	6.76e-05	0.000807	CbGpPWpGaD
Afatinib—Rash—Prednisone—systemic scleroderma	6.75e-05	0.0007	CcSEcCtD
Afatinib—Dermatitis—Prednisone—systemic scleroderma	6.74e-05	0.000699	CcSEcCtD
Afatinib—EGFR—Regulation of Telomerase—TGFB1—systemic scleroderma	6.71e-05	0.000801	CbGpPWpGaD
Afatinib—Headache—Prednisone—systemic scleroderma	6.71e-05	0.000695	CcSEcCtD
Afatinib—EGFR—Developmental Biology—RHOB—systemic scleroderma	6.68e-05	0.000797	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	6.63e-05	0.000792	CbGpPWpGaD
Afatinib—LCK—CXCR4-mediated signaling events—MMP9—systemic scleroderma	6.63e-05	0.000791	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—ITGAM—systemic scleroderma	6.56e-05	0.000783	CbGpPWpGaD
Afatinib—EPHA6—Axon guidance—MMP9—systemic scleroderma	6.53e-05	0.000779	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CSK—systemic scleroderma	6.47e-05	0.000772	CbGpPWpGaD
Afatinib—ERBB2—Axon guidance—MMP2—systemic scleroderma	6.43e-05	0.000767	CbGpPWpGaD
Afatinib—Asthenia—Methotrexate—systemic scleroderma	6.42e-05	0.000665	CcSEcCtD
Afatinib—ERBB4—Immune System—CSK—systemic scleroderma	6.37e-05	0.000761	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IRF5—systemic scleroderma	6.36e-05	0.00076	CbGpPWpGaD
Afatinib—Nausea—Prednisone—systemic scleroderma	6.36e-05	0.000659	CcSEcCtD
Afatinib—Pruritus—Methotrexate—systemic scleroderma	6.33e-05	0.000656	CcSEcCtD
Afatinib—LCK—Hemostasis—RHOB—systemic scleroderma	6.31e-05	0.000753	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IRF5—systemic scleroderma	6.27e-05	0.000748	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—HLA-DQB1—systemic scleroderma	6.26e-05	0.000747	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—MMP2—systemic scleroderma	6.2e-05	0.00074	CbGpPWpGaD
Afatinib—ERBB2—Disease—HSPG2—systemic scleroderma	6.18e-05	0.000738	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HLA-DQB1—systemic scleroderma	6.16e-05	0.000736	CbGpPWpGaD
Afatinib—BLK—Immune System—CSK—systemic scleroderma	6.13e-05	0.000732	CbGpPWpGaD
Afatinib—Diarrhoea—Methotrexate—systemic scleroderma	6.12e-05	0.000635	CcSEcCtD
Afatinib—ERBB4—Disease—HSPG2—systemic scleroderma	6.09e-05	0.000727	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IRF8—systemic scleroderma	6.08e-05	0.000726	CbGpPWpGaD
Afatinib—ERBB2—Immune System—ITGAM—systemic scleroderma	6.08e-05	0.000726	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD247—systemic scleroderma	6.08e-05	0.000726	CbGpPWpGaD
Afatinib—EGFR—Direct p53 effectors—MMP2—systemic scleroderma	6.08e-05	0.000726	CbGpPWpGaD
Afatinib—ERBB2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	6.07e-05	0.000725	CbGpPWpGaD
Afatinib—BLK—Immune System—IRF5—systemic scleroderma	6.03e-05	0.00072	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IRF8—systemic scleroderma	5.99e-05	0.000715	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD247—systemic scleroderma	5.99e-05	0.000715	CbGpPWpGaD
Afatinib—ERBB4—Immune System—ITGAM—systemic scleroderma	5.99e-05	0.000715	CbGpPWpGaD
Afatinib—ERBB2—Disease—CSK—systemic scleroderma	5.97e-05	0.000713	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—SMAD7—systemic scleroderma	5.94e-05	0.000709	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HLA-DQB1—systemic scleroderma	5.93e-05	0.000708	CbGpPWpGaD
Afatinib—ABL1—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	5.93e-05	0.000708	CbGpPWpGaD
Afatinib—Dizziness—Methotrexate—systemic scleroderma	5.92e-05	0.000613	CcSEcCtD
Afatinib—ERBB2—Adaptive Immune System—CD40LG—systemic scleroderma	5.91e-05	0.000705	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—ITGAM—systemic scleroderma	5.91e-05	0.000705	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CD247—systemic scleroderma	5.91e-05	0.000705	CbGpPWpGaD
Afatinib—ERBB4—Disease—CSK—systemic scleroderma	5.88e-05	0.000702	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—SMAD7—systemic scleroderma	5.85e-05	0.000698	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—CD40LG—systemic scleroderma	5.82e-05	0.000695	CbGpPWpGaD
Afatinib—BLK—Immune System—ITGAM—systemic scleroderma	5.76e-05	0.000688	CbGpPWpGaD
Afatinib—BLK—Immune System—IRF8—systemic scleroderma	5.76e-05	0.000688	CbGpPWpGaD
Afatinib—BLK—Immune System—CD247—systemic scleroderma	5.76e-05	0.000688	CbGpPWpGaD
Afatinib—LCK—Hemostasis—CSK—systemic scleroderma	5.75e-05	0.000686	CbGpPWpGaD
Afatinib—LCK—Signaling by Interleukins—IL1B—systemic scleroderma	5.75e-05	0.000686	CbGpPWpGaD
Afatinib—ERBB2—Immune System—TNFAIP3—systemic scleroderma	5.7e-05	0.00068	CbGpPWpGaD
Afatinib—Vomiting—Methotrexate—systemic scleroderma	5.69e-05	0.00059	CcSEcCtD
Afatinib—ABL1—Cell Cycle—TGFB1—systemic scleroderma	5.68e-05	0.000678	CbGpPWpGaD
Afatinib—Rash—Methotrexate—systemic scleroderma	5.64e-05	0.000585	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—systemic scleroderma	5.64e-05	0.000584	CcSEcCtD
Afatinib—ERBB2—Immune System—BLK—systemic scleroderma	5.63e-05	0.000672	CbGpPWpGaD
Afatinib—ERBB2—Disease—CD247—systemic scleroderma	5.62e-05	0.00067	CbGpPWpGaD
Afatinib—ERBB4—Immune System—TNFAIP3—systemic scleroderma	5.61e-05	0.00067	CbGpPWpGaD
Afatinib—Headache—Methotrexate—systemic scleroderma	5.61e-05	0.000581	CcSEcCtD
Afatinib—BLK—Adaptive Immune System—CD40LG—systemic scleroderma	5.6e-05	0.000668	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—IL1B—systemic scleroderma	5.56e-05	0.000663	CbGpPWpGaD
Afatinib—ERBB4—Immune System—BLK—systemic scleroderma	5.54e-05	0.000662	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—TNFAIP3—systemic scleroderma	5.53e-05	0.00066	CbGpPWpGaD
Afatinib—ERBB4—Disease—CD247—systemic scleroderma	5.53e-05	0.00066	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	5.41e-05	0.000646	CbGpPWpGaD
Afatinib—LCK—Hemostasis—ITGAM—systemic scleroderma	5.4e-05	0.000645	CbGpPWpGaD
Afatinib—BLK—Immune System—TNFAIP3—systemic scleroderma	5.4e-05	0.000644	CbGpPWpGaD
Afatinib—ABL1—DNA Damage Response (only ATM dependent)—TGFB1—systemic scleroderma	5.38e-05	0.000643	CbGpPWpGaD
Afatinib—Nausea—Methotrexate—systemic scleroderma	5.31e-05	0.000551	CcSEcCtD
Afatinib—EGFR—Spinal Cord Injury—MMP9—systemic scleroderma	5.24e-05	0.000625	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CSK—systemic scleroderma	5.16e-05	0.000615	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	5.14e-05	0.000614	CbGpPWpGaD
Afatinib—EGFR—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	5.07e-05	0.000605	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—ITGAM—systemic scleroderma	5.05e-05	0.000603	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CD247—systemic scleroderma	5.05e-05	0.000603	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CSK—systemic scleroderma	4.97e-05	0.000593	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CD247—systemic scleroderma	4.87e-05	0.000581	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—ITGAM—systemic scleroderma	4.87e-05	0.000581	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD247—systemic scleroderma	4.85e-05	0.000579	CbGpPWpGaD
Afatinib—ERBB2—Axon guidance—MMP9—systemic scleroderma	4.83e-05	0.000577	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—TNFAIP3—systemic scleroderma	4.73e-05	0.000564	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CSK—systemic scleroderma	4.68e-05	0.000558	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD247—systemic scleroderma	4.67e-05	0.000558	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—MMP9—systemic scleroderma	4.66e-05	0.000556	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CTLA4—systemic scleroderma	4.61e-05	0.00055	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IRF5—systemic scleroderma	4.6e-05	0.000549	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—RHOB—systemic scleroderma	4.59e-05	0.000548	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—MMP2—systemic scleroderma	4.59e-05	0.000547	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—TNFAIP3—systemic scleroderma	4.56e-05	0.000544	CbGpPWpGaD
Afatinib—EGFR—Signaling by SCF-KIT—MMP9—systemic scleroderma	4.54e-05	0.000542	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CTLA4—systemic scleroderma	4.54e-05	0.000542	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—RHOB—systemic scleroderma	4.52e-05	0.00054	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—BLK—systemic scleroderma	4.49e-05	0.000535	CbGpPWpGaD
Afatinib—IRAK1—Immune System—ITGAM—systemic scleroderma	4.4e-05	0.000525	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IRF8—systemic scleroderma	4.4e-05	0.000525	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD247—systemic scleroderma	4.4e-05	0.000525	CbGpPWpGaD
Afatinib—LCK—Signaling by SCF-KIT—MMP9—systemic scleroderma	4.38e-05	0.000523	CbGpPWpGaD
Afatinib—BLK—Immune System—CTLA4—systemic scleroderma	4.37e-05	0.000521	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HSPG2—systemic scleroderma	4.33e-05	0.000517	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—BLK—systemic scleroderma	4.32e-05	0.000516	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—TGFB1—systemic scleroderma	4.32e-05	0.000515	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SMAD7—systemic scleroderma	4.29e-05	0.000512	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HSPG2—systemic scleroderma	4.27e-05	0.000509	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—IL1B—systemic scleroderma	4.19e-05	0.0005	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CSK—systemic scleroderma	4.18e-05	0.000499	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	4.16e-05	0.000497	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CSK—systemic scleroderma	4.12e-05	0.000492	CbGpPWpGaD
Afatinib—IRAK1—Immune System—TNFAIP3—systemic scleroderma	4.12e-05	0.000492	CbGpPWpGaD
Afatinib—PHKG2—Disease—NOS3—systemic scleroderma	4.11e-05	0.000491	CbGpPWpGaD
Afatinib—EGFR—Disease—SMAD7—systemic scleroderma	4.1e-05	0.000489	CbGpPWpGaD
Afatinib—IRAK1—Immune System—BLK—systemic scleroderma	4.07e-05	0.000486	CbGpPWpGaD
Afatinib—LCK—Disease—SMAD7—systemic scleroderma	3.95e-05	0.000471	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	3.87e-05	0.000461	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—TGFB1—systemic scleroderma	3.84e-05	0.000458	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HLA-DQB1—systemic scleroderma	3.8e-05	0.000453	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—RHOB—systemic scleroderma	3.76e-05	0.000449	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFBI—systemic scleroderma	3.75e-05	0.000447	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HLA-DQB1—systemic scleroderma	3.74e-05	0.000446	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CTLA4—systemic scleroderma	3.67e-05	0.000439	CbGpPWpGaD
Afatinib—ABL1—Immune System—CSK—systemic scleroderma	3.66e-05	0.000437	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—MMP2—systemic scleroderma	3.64e-05	0.000434	CbGpPWpGaD
Afatinib—LCK—Disease—TGFBI—systemic scleroderma	3.61e-05	0.000431	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL1A—systemic scleroderma	3.61e-05	0.00043	CbGpPWpGaD
Afatinib—ABL1—Immune System—IRF5—systemic scleroderma	3.6e-05	0.00043	CbGpPWpGaD
Afatinib—BLK—Immune System—HLA-DQB1—systemic scleroderma	3.6e-05	0.000429	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD40LG—systemic scleroderma	3.58e-05	0.000428	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL1A—systemic scleroderma	3.55e-05	0.000424	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CTLA4—systemic scleroderma	3.54e-05	0.000423	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD40LG—systemic scleroderma	3.53e-05	0.000421	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—MMP9—systemic scleroderma	3.45e-05	0.000411	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—NOS3—systemic scleroderma	3.45e-05	0.000411	CbGpPWpGaD
Afatinib—ABL1—Immune System—IRF8—systemic scleroderma	3.44e-05	0.000411	CbGpPWpGaD
Afatinib—ABL1—Immune System—ITGAM—systemic scleroderma	3.44e-05	0.000411	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD247—systemic scleroderma	3.44e-05	0.000411	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.44e-05	0.00041	CbGpPWpGaD
Afatinib—BLK—Immune System—IL1A—systemic scleroderma	3.42e-05	0.000408	CbGpPWpGaD
Afatinib—BLK—Immune System—CD40LG—systemic scleroderma	3.4e-05	0.000405	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CTLA4—systemic scleroderma	3.33e-05	0.000398	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—RHOB—systemic scleroderma	3.32e-05	0.000396	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—MMP1—systemic scleroderma	3.29e-05	0.000393	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TGFB1—systemic scleroderma	3.25e-05	0.000388	CbGpPWpGaD
Afatinib—ABL1—Immune System—TNFAIP3—systemic scleroderma	3.22e-05	0.000385	CbGpPWpGaD
Afatinib—ABL1—Immune System—BLK—systemic scleroderma	3.18e-05	0.00038	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HSPG2—systemic scleroderma	3.13e-05	0.000374	CbGpPWpGaD
Afatinib—EGFR—Immune System—CSK—systemic scleroderma	3.13e-05	0.000373	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—MMP2—systemic scleroderma	3.11e-05	0.000371	CbGpPWpGaD
Afatinib—EGFR—Immune System—IRF5—systemic scleroderma	3.08e-05	0.000367	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-DQB1—systemic scleroderma	3.03e-05	0.000361	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CSK—systemic scleroderma	3.02e-05	0.000361	CbGpPWpGaD
Afatinib—LCK—Immune System—CSK—systemic scleroderma	3.01e-05	0.00036	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	3e-05	0.000359	CbGpPWpGaD
Afatinib—EGFR—Disease—HSPG2—systemic scleroderma	2.99e-05	0.000357	CbGpPWpGaD
Afatinib—LCK—Immune System—IRF5—systemic scleroderma	2.97e-05	0.000354	CbGpPWpGaD
Afatinib—EGFR—Immune System—IRF8—systemic scleroderma	2.94e-05	0.000351	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD247—systemic scleroderma	2.94e-05	0.000351	CbGpPWpGaD
Afatinib—EGFR—Immune System—ITGAM—systemic scleroderma	2.94e-05	0.000351	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.94e-05	0.000351	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HLA-DQB1—systemic scleroderma	2.92e-05	0.000348	CbGpPWpGaD
Afatinib—EGFR—Disease—CSK—systemic scleroderma	2.89e-05	0.000345	CbGpPWpGaD
Afatinib—LCK—Disease—HSPG2—systemic scleroderma	2.88e-05	0.000344	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SMAD7—systemic scleroderma	2.87e-05	0.000343	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD40LG—systemic scleroderma	2.86e-05	0.000341	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—TGFB1—systemic scleroderma	2.84e-05	0.000339	CbGpPWpGaD
Afatinib—LCK—Immune System—IRF8—systemic scleroderma	2.83e-05	0.000338	CbGpPWpGaD
Afatinib—LCK—Immune System—CD247—systemic scleroderma	2.83e-05	0.000338	CbGpPWpGaD
Afatinib—LCK—Immune System—ITGAM—systemic scleroderma	2.83e-05	0.000338	CbGpPWpGaD
Afatinib—LCK—Disease—CSK—systemic scleroderma	2.78e-05	0.000332	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SMAD7—systemic scleroderma	2.77e-05	0.00033	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD40LG—systemic scleroderma	2.75e-05	0.000329	CbGpPWpGaD
Afatinib—EGFR—Immune System—TNFAIP3—systemic scleroderma	2.75e-05	0.000329	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-DQB1—systemic scleroderma	2.74e-05	0.000328	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—MMP9—systemic scleroderma	2.73e-05	0.000326	CbGpPWpGaD
Afatinib—PHKG2—Disease—TGFB1—systemic scleroderma	2.72e-05	0.000325	CbGpPWpGaD
Afatinib—EGFR—Immune System—BLK—systemic scleroderma	2.72e-05	0.000325	CbGpPWpGaD
Afatinib—EGFR—Disease—CD247—systemic scleroderma	2.71e-05	0.000324	CbGpPWpGaD
Afatinib—LCK—Hemostasis—MMP1—systemic scleroderma	2.71e-05	0.000323	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	2.68e-05	0.00032	CbGpPWpGaD
Afatinib—LCK—Immune System—TNFAIP3—systemic scleroderma	2.65e-05	0.000317	CbGpPWpGaD
Afatinib—LCK—Immune System—BLK—systemic scleroderma	2.62e-05	0.000313	CbGpPWpGaD
Afatinib—LCK—Disease—CD247—systemic scleroderma	2.62e-05	0.000312	CbGpPWpGaD
Afatinib—ABL1—Immune System—CTLA4—systemic scleroderma	2.61e-05	0.000311	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL1A—systemic scleroderma	2.61e-05	0.000311	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—MMP2—systemic scleroderma	2.59e-05	0.00031	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD40LG—systemic scleroderma	2.59e-05	0.000309	CbGpPWpGaD
Afatinib—LCK—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	2.52e-05	0.000301	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—NOS3—systemic scleroderma	2.38e-05	0.000285	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EDN1—systemic scleroderma	2.34e-05	0.00028	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—HSPG2—systemic scleroderma	2.34e-05	0.000279	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—MMP9—systemic scleroderma	2.33e-05	0.000279	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EDN1—systemic scleroderma	2.31e-05	0.000276	CbGpPWpGaD
Afatinib—EGFR—Immune System—CTLA4—systemic scleroderma	2.23e-05	0.000266	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RHOB—systemic scleroderma	2.22e-05	0.000265	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—MMP2—systemic scleroderma	2.22e-05	0.000265	CbGpPWpGaD
Afatinib—LCK—Immune System—CTLA4—systemic scleroderma	2.15e-05	0.000256	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-DQB1—systemic scleroderma	2.15e-05	0.000256	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RHOB—systemic scleroderma	2.14e-05	0.000255	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HSPG2—systemic scleroderma	2.09e-05	0.00025	CbGpPWpGaD
Afatinib—ERBB2—Disease—NOS3—systemic scleroderma	2.04e-05	0.000244	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1A—systemic scleroderma	2.04e-05	0.000243	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD40LG—systemic scleroderma	2.03e-05	0.000242	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CSK—systemic scleroderma	2.02e-05	0.000241	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HSPG2—systemic scleroderma	2.02e-05	0.000241	CbGpPWpGaD
Afatinib—ERBB4—Disease—NOS3—systemic scleroderma	2.01e-05	0.00024	CbGpPWpGaD
Afatinib—LCK—Hemostasis—NOS3—systemic scleroderma	1.96e-05	0.000234	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—MMP9—systemic scleroderma	1.95e-05	0.000233	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CSK—systemic scleroderma	1.95e-05	0.000233	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—EDN1—systemic scleroderma	1.92e-05	0.000229	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL1B—systemic scleroderma	1.88e-05	0.000224	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL1B—systemic scleroderma	1.85e-05	0.000221	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-DQB1—systemic scleroderma	1.84e-05	0.000219	CbGpPWpGaD
Afatinib—BLK—Immune System—IL1B—systemic scleroderma	1.78e-05	0.000213	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CTGF—systemic scleroderma	1.77e-05	0.000211	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-DQB1—systemic scleroderma	1.77e-05	0.000211	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1A—systemic scleroderma	1.74e-05	0.000208	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD40LG—systemic scleroderma	1.73e-05	0.000207	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EDN1—systemic scleroderma	1.7e-05	0.000202	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1A—systemic scleroderma	1.68e-05	0.000201	CbGpPWpGaD
Afatinib—LCK—Immune System—CD40LG—systemic scleroderma	1.67e-05	0.000199	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—MMP9—systemic scleroderma	1.67e-05	0.000199	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TGFB1—systemic scleroderma	1.61e-05	0.000192	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CCL2—systemic scleroderma	1.6e-05	0.000191	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CCL2—systemic scleroderma	1.58e-05	0.000188	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TGFB1—systemic scleroderma	1.58e-05	0.000188	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.48e-05	0.000177	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NOS3—systemic scleroderma	1.43e-05	0.000171	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NOS3—systemic scleroderma	1.41e-05	0.000168	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TGFB1—systemic scleroderma	1.37e-05	0.000164	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL1B—systemic scleroderma	1.36e-05	0.000162	CbGpPWpGaD
Afatinib—ERBB2—Disease—TGFB1—systemic scleroderma	1.35e-05	0.000161	CbGpPWpGaD
Afatinib—ERBB4—Disease—TGFB1—systemic scleroderma	1.33e-05	0.000159	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CCL2—systemic scleroderma	1.31e-05	0.000157	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TGFB1—systemic scleroderma	1.3e-05	0.000155	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HSPG2—systemic scleroderma	1.26e-05	0.000151	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCL2—systemic scleroderma	1.16e-05	0.000138	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MMP9—systemic scleroderma	1.15e-05	0.000137	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EDN1—systemic scleroderma	1.13e-05	0.000135	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MMP9—systemic scleroderma	1.13e-05	0.000135	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EDN1—systemic scleroderma	1.09e-05	0.00013	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1B—systemic scleroderma	1.06e-05	0.000127	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NOS3—systemic scleroderma	1.03e-05	0.000123	CbGpPWpGaD
Afatinib—EGFR—Disease—NOS3—systemic scleroderma	9.86e-06	0.000118	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CTGF—systemic scleroderma	9.58e-06	0.000114	CbGpPWpGaD
Afatinib—LCK—Disease—NOS3—systemic scleroderma	9.5e-06	0.000113	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TGFB1—systemic scleroderma	9.45e-06	0.000113	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TGFB1—systemic scleroderma	9.3e-06	0.000111	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1B—systemic scleroderma	9.09e-06	0.000109	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1B—systemic scleroderma	8.76e-06	0.000105	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—systemic scleroderma	8.29e-06	9.89e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL2—systemic scleroderma	7.75e-06	9.25e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—NOS3—systemic scleroderma	7.71e-06	9.2e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL2—systemic scleroderma	7.47e-06	8.91e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOS3—systemic scleroderma	6.91e-06	8.24e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TGFB1—systemic scleroderma	6.83e-06	8.15e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOS3—systemic scleroderma	6.66e-06	7.94e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFB1—systemic scleroderma	6.52e-06	7.78e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TGFB1—systemic scleroderma	6.28e-06	7.5e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—systemic scleroderma	5.54e-06	6.61e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—systemic scleroderma	5.34e-06	6.37e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFB1—systemic scleroderma	4.57e-06	5.45e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFB1—systemic scleroderma	4.4e-06	5.25e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NOS3—systemic scleroderma	4.17e-06	4.98e-05	CbGpPWpGaD
